Humanwell Healthcare Group has been granted a patent for a clear bioavailable liquid composition containing active ingredients like guaifenesin and phenylephrine HCl. The formulation is designed to remain clear without recrystallization for up to two years at room temperature, enhancing its stability and usability. GlobalData’s report on Humanwell Healthcare Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Humanwell Healthcare Group, Cancer treatment biomarkers was a key innovation area identified from patents. Humanwell Healthcare Group's grant share as of June 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Bioavailable liquid compositions for respiratory relief
The granted patent US12005037B2 outlines a clear bioavailable liquid composition designed for pharmaceutical applications. The composition includes active ingredients such as guaifenesin, which is present in varying concentrations between 21 wt % to 25 wt %, combined with other active agents like phenylephrine HCl, dextromethorphan HBr, or pseudoephedrine HCl. The formulation also incorporates a matrix consisting of a pharmaceutically acceptable poly(alkylene glycol) and an alkylene glycol, along with a polymeric solubilizing agent, specifically polyvinylpyrrolidone. Notably, the composition is engineered to remain clear and stable without recrystallization for up to two years at room temperature, ensuring its efficacy and usability over an extended period.
Additionally, the patent details specific formulations of the liquid composition, providing examples of precise ingredient quantities for different variations. For instance, one formulation includes 200 mg of guaifenesin, 5.13 mg of phenylephrine HCl, and other components totaling 860 mg. Other variations include combinations with dextromethorphan HBr and pseudoephedrine HCl, maintaining the overall clarity and stability of the liquid. Furthermore, the patent also describes a pharmaceutical composition in the form of a soft gelatin capsule, which encapsulates the clear bioavailable liquid composition, allowing for convenient administration. This innovative formulation aims to enhance the delivery and effectiveness of the active ingredients in treating various conditions.
To know more about GlobalData’s detailed insights on Humanwell Healthcare Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
